Biogen Inc.

IDP.DE·XETRA·Healthcare
Compare
229.25+6.20 (+2.78%)today
As of Nov 5, 10:38 AM CET · May be delayed up to 15 min · EUR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close223.05
Open226.40
Day range226.40229.25
52-week range129.55231.10
Off day high0.00%
Off 52-week high−0.80%
Volume500
Avg. volume (3M)100
Market cap33.89B
EPS (TTM)2.01
Forward P/E—
P/E ratio (TTM)114.05
Dividend yield—
Beta (5Y)0.09
Shares outstanding147.82M
Short interest—
Earnings dateOct 28, 2026
Analyst target—
Profit margin3.38%

Against its peers

Compare in full ›
IDP.DE AMGN BMY SNW.F NVS LLY
Market cap 33.89B 258.82B 131.21B 101.16B 311.59B 1.26T
P/E (TTM) 114.1 27.7 14.2 24.4 31.5 46.0
Forward P/E — 19.4 9.6 9.8 16.6 28.3
Price/book 2.0 18.0 5.6 1.4 8.4 31.4
Dividend yield — 2.11% 3.93% 5.11% 2.87% 0.49%
1-year change +69.60% +51.61% +37.66% −2.66% +30.35% +51.26%
Today +2.78% +3.73% +4.02% +1.21% +3.59% +0.61%

The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.

Related companies

Compare ›

The businesses closest to Biogen's by what they do, from their descriptions, with the same industry weighted in.

Company Mkt cap Price Today
Amgen Inc.AMGN · Drug Manufacturers - General 258.82B 478.48 +3.73%
Bristol-Myers Squibb CompanyBMY · Drug Manufacturers - General 131.21B 64.19 +4.02%
SanofiSNW.F · Drug Manufacturers - General 101.16B 84.44 +1.21%
Novartis AGNVS · Drug Manufacturers - General 311.59B 164.98 +3.59%
Eli Lilly and CompanyLLY · Drug Manufacturers - GeneralOdds 1.26T 1,417.99 +0.61%
AbbVie Inc.0QCV.IL · Drug Manufacturers - General 539.67B 299.99 +5.63%
Roivant Sciences Ltd.ROIV · Biotechnology 27.61B 38.23 +6.08%
BioArctic AB (publ)B9A.F · Biotechnology 2.45B 27.58 −0.29%

Also based in Cambridge, Massachusetts, then elsewhere in Massachusetts.

Company Mkt cap Price Today
Moderna, Inc.MRNA · Cambridge, MAOdds 103.15B 258.38 +13.11%
Akamai Technologies, Inc.AKAM · Cambridge, MAOdds 12.35B 85.93 −0.69%
GE Vernova Inc.GEV · Cambridge, MA 220.43B 832.83 −9.30%
Alnylam Pharmaceuticals, Inc.ALNY · Cambridge, MAOdds 21.57B 161.08 +0.74%
HubSpot, Inc.HUBS · Cambridge, MA 11.09B 216.64 −4.21%
Nuvalent IncNUVL · Cambridge, MA 9.81B 123.96 0.00%
Scholar Rock Holding CorporationSRRK · Cambridge, MA 5.61B 46.09 +4.80%
Relay Therapeutics, Inc.RLAY · Cambridge, MA 3.95B 18.03 +3.38%

The stocks whose daily moves over the past year went most closely with Biogen's: the correlation of their daily returns, where 1 would be moving as one.

Company Mkt cap Price Today
Biogen Inc.IDP.F · Correlation 0.52 33.18B 224.45 +0.25%
Amgen Inc.AMG.DE · Correlation 0.32 228.96B 423.50 +2.12%
Johnson & JohnsonJNJ.DE · Correlation 0.32 600.86B 249.60 +2.93%
Gilead Sciences, Inc.GIS.DE · Correlation 0.32 191.71B 154.56 +1.62%

What visitors to Biogen's page also look at.

Company Mkt cap Price Today
GILEAD SCIENCES INC.GIS.DE 191.71B 154.56 +1.62%
Biogen Inc.IDP.F 33.18B 224.45 +0.25%
AMGEN INC.AMG.DE 228.96B 423.50 +2.12%
BRISTOL-MYERS SQUIBB CO.BRM.DE 117.43B 57.45 +2.44%
JOHNSON & JOHNSONJNJ.DE 600.86B 249.60 +2.93%

From the 4Search instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 20 min.

Latest news

All IDP.DE news ›
FinancialContent·Positive

Biogen (BIIB) Stock Is Up, What You Need To Know

Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neutral with a $300 price target, raised from $210. As detailed by Investing.com, Schott observed in…

BIIBGILDAMGNABBV
Longevity.Technology·Positive

Biogen to share long-term trial results for its Alzheimer’s drugs

Biogen will present new data across its Alzheimer’s disease portfolio at the 19th Clinical Trials on Alzheimer’s Disease conference, 16–19 November 2026, in Boston. Presentations will include expanded results from the Phase 2 CELIA study…

BIIB
The Globe and Mail·Negative

Stifel Nicolaus Sticks to Their Buy Rating for Biogen (BIIB)

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Biogen yesterday and set a price target of $286.00. Matteis covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Contineum Therapeutics, Inc. Class A, and…

BIIBBCS
The Globe and Mail·Negative

Biogen (BIIB) Receives a Buy from Needham

In a report released today, Ami Fadia from Needham reiterated a Buy rating on Biogen, with a price target of $290.00. According to TipRanks, Fadia is a 5-star analyst with an average return of 30.0% and a 54.46% success rate. Fadia covers…

BIIBBCSPFE
The Globe and Mail·Negative

UBS Remains a Buy on Biogen (BIIB)

UBS analyst Michael Yee maintained a Buy rating on Biogen today and set a price target of $300.00. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Amgen, and Bristol-Myers Squibb. According to TipRanks,…

BIIBURGN

From the 4Search news index, newest first.

In the news

115mentions in 30 days
115with it in the headline
Positivesentiment

Mentioned with

Biogen Inc.52Eli Lilly44Pfizer37Amgen Inc.34Vertex Pharmaceuticals34Barclays29Gilead Sciences29Abbvie Inc.28

People in the coverage

Kim Johansen61Danessa Lincoln60Sarita Garza55Tristan Rich44Benzinga43Piper Sandler43

Themes

Healthcare61Biib49All News and Stock Ideas32Biotech and Pharma Stock News28Earnings26Finanzen22Consensus21Lly20

Most coverage from

  1. marketscreener.com19
  2. theglobeandmail.com13
  3. markets.businessinsider.com10
  4. seekingalpha.com8
  5. kalkinemedia.com4

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 115 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use. How to use Finance